IMGN News and Press, ImmunoGen Inc. From 05/24/23

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthca...

2023-05-19 10:00:52 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affe...

2023-05-15 13:44:44 ET Shares of the SPDR S&P Biotech ETF ( NYSEARCA: XBI ) moved up to a new 3-month trading high on Monday afternoon as the exchange traded fund picked up 3.5% on the day. Moreover, the fund opened trading at $85.72 a share and moved up to $88.20 a...

A significant medical breakthrough is desperately needed in the fight against breast cancer. At the moment, according to the American Cancer Society, more than 3.1 million women in the United States alone have a history of invasive breast cancer. And unfortunately, as it stands, breast cancer dea...

2023-05-14 21:08:03 ET Summary The Regional Bank Fiasco is a classic “Baby with the Bathwater” scenario. Rising rates are great for Insurance companies and “hidden banks”. Since ETFs are a very popular way to participate in the market, whole sectors are...

2023-05-12 11:20:28 ET Summary ImmunoGen, Inc. lead drug (Elahere) recently gained accelerated approval to treat patients afflicted by platinum-resistant ovarian cancers with the high FRA expression. The Q1 earnings report showed that the blockbuster prospect (Elahere) is gaining ...

2023-05-10 07:03:05 ET Cerevel Therapeutics ( NASDAQ: CERE ) appointed Susan Altschuller as CFO, effective May 15. Altschuller previously served as CFO of ImmunoGen ( IMGN ) and has also worked at Alexion, now a part of AstraZeneca. Mark Bodenrader ...

2023-05-09 14:36:35 ET Summary ImmunoGen, Inc. ELAHERE succeeds in phase 3 confirmatory MIRASOL trial; all endpoints achieved with statistical significance when FRa-high positive platinum-resistant ovarian cancer patients received ELAHERE. Submission of BLA of ELAHERE to the FDA t...

Data from Confirmatory Trial to be Highlighted in Oral Presentation on Sunday, June 4 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase 3 confirmatory MIRASOL tr...

2023-05-04 10:31:45 ET Summary ImmunoGen released some outstanding Phase 3 data in relation to its only approved asset ELAHERE yesterday. In its MIRASOL study, ELAHERE met its primary endpoint of Progression Free Survival, as well as the key secondary endpoint of Overall Survival ...